PAVM Stock Risk & Deep Value Analysis
PAVmed Inc
Healthcare • Medical Devices
DVR Score
out of 10
What You Need to Know About PAVM Stock
We analyzed PAVmed Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PAVM through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
How Risky Is PAVM Stock?
Overall Risk
Aggressive
Financial Risk
High
Market Risk
Medium
Competitive Risk
High
Execution Risk
High
Regulatory Risk
Medium
What Are the Red Flags for PAVM?
- âš
Further equity dilution to fund operations
- âš
Failure to secure adequate financing
- âš
Continued low adoption rates for Lucid Diagnostics products
- âš
Delisting from major exchange due to market cap or financial non-compliance
Unlock PAVM Red Flags & Risk Warnings
Create a free account to see the full analysis
What Does PAVmed Inc (PAVM) Do?
Market Cap
$7.91M
Sector
Healthcare
Industry
Medical Devices
Employees
39
PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York
Visit PAVmed Inc WebsiteIs PAVM Stock Undervalued?
Unlock the full AI analysis for PAVM
Get the complete DVR score, risk analysis, and more
Does PAVM Have a Competitive Moat?
Sign in to unlockMoat Rating
⚪ None
Moat Trend
Eroding
Moat Sources
1 Identified
While FDA clearance provides a barrier to entry, the company's inability to commercialize effectively means the IP is not translating into a durable competitive advantage. The moat is eroding due to financial fragility and operational struggles, making it vulnerable to better-funded competitors.
Moat Erosion Risks
- •Failure to secure sufficient funding to scale commercialization
- •Competitors developing superior or more cost-effective screening solutions
- •Inability to achieve broad adoption and reimbursement for products
PAVM Competitive Moat Analysis
Sign up to see competitive advantages
What Could Drive PAVM Stock Higher?
Near-Term (0-6 months)
- •Q4 2025 Earnings Report (Estimated late-March 2026)
- •Potential new financing round announcement
Medium-Term (6-18 months)
- •Significant acceleration in EsoGuard/EsoCure commercialization
- •Strategic partnership for broader market penetration
Long-Term (18+ months)
- •Establishment of EsoGuard as a standard of care for esophageal cancer screening
- •Expansion of product pipeline or indications
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PAVM?
- ✓
Announcement of significant non-dilutive financing or major strategic partnership
- ✓
Quarterly reports showing accelerating revenue growth for EsoGuard and declining cash burn
- ✓
Expansion of insurance coverage and reimbursement for Lucid Diagnostics products
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PAVM (PAVmed Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.
